Until recently, the principal causes of degenerative disease were thought to act in adult life and to accelerate destructive processes, such as the formation of atheroma and rise in blood pressure. Recent observations that people who develop coronary heart disease grow differently to other people during fetal life and childhood have, however, led to a new ‘developmental’ model for the disease. Low birthweight has been shown to be associated with increased rates of coronary heart disease, type 2 diabetes mellitus and altered glucose tolerance. These associations with low birthweight extend across the normal range of birthweight and reflect slow fetal growth rather than premature birth. The associations are thought to be consequences of developmental plasticity, the phenomenon by which one genotype can give rise to a range of different physiological or morphological states in response to different environmental conditions during development. Recent observations suggest that low birthweight, thinness at 2 years of age and an increase in body mass index (BMI) after the age of 2 years are each associated with the development of insulin resistance in later life. The prevention of a substantial proportion of type 2 diabetes and other disorders linked to insulin resistance may, therefore, depend on interventions during development. These include protecting the growth of babies during the first 2 years after birth by good infant feeding practices and preventing a rapid increase in BMI after the age of 2 years. Improving fetal nutrition remains an important long-term goal.

Keywords:
Fetal growth, Childhood growth, Insulin resistance, Type 2 diabetes mellitus, Body mass index
1.
Ebrahim S, Davey Smith G: Systematic review of randomised controlled trials of multiple risk factor interventions for preventing coronary heart disease. BMJ 1997;314:1666–1674.
2.
Barker DJP: Mothers, Babies and Health in Later Life. Edinburgh, Churchill Livingstone, 1998.
3.
Barker DJP, Osmond C, Winter PD, Margetts B, Simmonds SJ: Weight in infancy and death from ischaemic heart disease. Lancet 1989;2:577–580.
4.
Osmond C, Barker DJ, Winter PD, Fall CHD, Simmonds SJ: Early growth and death from cardiovascular disease in women. BMJ 1993;307:1519–1524.
5.
Frankel S, Elwood P, Sweetnam P, Yarnell J, Davey Smith G: Birthweight, body mass index in middle age, and incident coronary heart disease. Lancet 1996;348:1478–1480.
6.
Rich-Edwards JW, Stampfer MJ, Manson JE, Rosner B, Hankinson SE, Colditz GA, Willett WC, Hennekens CH: Birth weight and risk of cardiovascular disease in a cohort of women followed up since 1976. BMJ 1997;315:396–400.
7.
Stein CE, Fall CHD, Kumaran K, Osmond C, Cox V, Barker DJP: Fetal growth and coronary heart disease in South India. Lancet 1996;48:1269–1273.
8.
Leon DA, Lithell HO, Vagero D, Koupilova I, Mohsen R, Berglund L, Lithell UB, McKeigue PM: Reduced fetal growth rate and increased risk of death from ischaemic heart disease: cohort study of 15,000 Swedish men and women born 1915-29. BMJ 1998;317:241–245.
9.
Forsén T, Eriksson JG, Tuomilehto J, Teramo K, Osmond C, Barker DJP: Mother’s weight in pregnancy and coronary heart disease in a cohort of Finnish men: Follow-up study. BMJ 1997;315:837–840.
10.
Forsén T, Osmond C, Eriksson JG, Barker DJP: Growth of girls who later develop coronary heart disease. Heart 2004;90:20–24.
11.
Eriksson JG, Forsén T, Tuomilehto J, Osmond C, Barker DJP: Early growth and coronary heart disease in later life: Longitudinal study. BMJ 2001;322:949–953.
12.
Hales CN, Barker DJP, Clark PM, Cox LJ, Fall C, Osmond C, Winter PD: Fetal and infant growth and impaired glucose tolerance at age 64. BMJ 1991;303:1019–1022.
13.
Lithell HO, McKeigue PM, Berglund L, Mohsen R, Lithell UB, Leon DA: Relation of size at birth to non-insulin dependent diabetes and insulin concentrations in men aged 50–60 years. BMJ 1996;312:406–410.
14.
McCance DR, Pettitt DJ, Hanson RL, Jacobsson LTH, Knowler WC, Bennett PH: Birth weight and non-insulin dependent diabetes: thrifty genotype, thrifty phenotype, or surviving small baby genotype? BMJ 1994;308:942–945.
15.
Rich-Edwards JW, Colditz GA, Stampfer MJ, Willett WC, Gillman MW, Hennekens CH, Speizer FE, Manson JE: Birthweight and the risk for type 2 diabetes mellitus in adult women. Ann Intern Med 1999;130:278–284.
16.
Forsén T, Eriksson J, Tuomilehto J, Reunanen A, Osmond C, Barker D: The fetal and childhood growth of persons who develop type 2 diabetes. AnnIntern Med 2000;133:176–182.
17.
Newsome CA, Shiell AW, Fall CHD, Phillips DIW, Shier R, Law CM: Is birthweight related to later glucose and insulin metabolism – a systematic review. Diabet Med 2003;20:339–348.
18.
West-Eberhard MJ: Phenotypic plasticity and the origins of diversity. Ann Rev Ecolo System 1989;20:249.
19.
Bateson P, Martin P:Design For a Life: How Behaviour Develops. London, Jonathan Cape, 1999.
20.
Bertram CE, Hanson MA: Animal models and the programming of the metabolic syndrome; in Barker DJP (ed): Type 2 Diabetes: The Thrifty Phenotype. Br Med Bull 2001;60:103–121.
21.
Hanson MA, Hoet JJ: Intrauterine nutrition: its importance during critical periods for cardiovascular and endocrine development. J Physiol 1999;514:617–627.
22.
Barker DJP: Fetal origins of coronary heart disease. BMJ 1995;311:171–174.
23.
Barker DJP, Eriksson JG, Forsén T, Osmond C: Fetal origins of adult disease: Strength of effects and biological basis. Int J Epidemiol 2002;31:1235–1239.
24.
Brenner BM, Chertow GM: Congenital oligonephropathy: An inborn cause of adult hypertension and progressive renal injury? Curr Opin Nephrol Hypertens 1993;2:691–695.
25.
Ingelfinger JR: Is microanatomy destiny? N Engl J Med 2003;348:99–100.
26.
Moritz KM, Dodic M, Wintour EM: Kidney development and the fetal programming of adult disease.Bioessays 2003;25:212–220.
27.
Phillips DIW: Insulin resistance as a programmed response to fetal undernutrition. Diabetologia 1996;39:1119–1122.
28.
Barker DJP, Forsen T, Uutela A, Osmond C, Eriksson JG: Small size at birth and resilience to the effects of poor living conditions in adult life: longitudinal study. BMJ 2001;323:1273–1276.
29.
Marmot M, Wilkinson RG: Psychosocial and material pathways in the relation between income and health. BMJ 2001;322:1233–1236.
30.
Eriksson JG, Forsén T, Tuomilehto J, Osmond C, Barker DJP: Early adiposity rebound in childhood and risk of type 2 diabetes in adult life. Diabetologia 2003;46:190–194.
31.
Rolland-Cachera MF, Deheeger M, Guilloud-Bataille M, Avons P, Patois E, Sempe M: Tracking the development of adiposity from one month of age to adulthood. Ann Hum Biol 1987;14:219–229.
32.
Barker DJP, Osmond C, Forsén TJ, Kajantie E, Eriksson JG: Trajectories of growth among children who later developed coronary heart disease or its risk factors. N Engl J Med 2005; 353:1802–1809.
33.
Eriksson JG, Forsén T, Osmond C, Barker DJP: Pathways of infant and childhood growth that lead to type 2 diabetes. Diabetes Care 2003;26:3006–3010.
34.
Metcalfe NB, Monaghan P: Compensation for a bad start: grow now, pay later? Trends Ecol Evol 2001;16:254–260.
35.
Widdowson EM, Crabb DE, Milner RDG: Cellular development of some human organs before birth. Arch Dis Child 1972;47:652–655.
36.
Eriksson JG, Forsén T, Jaddoe VWV, Osmond C, Barker DJP: Effects of size at birth and childhood growth on the insulin resistance syndrome in elderly individuals. Diabetologia 2002;45:342–348.
37.
Eriksson JG, Lindi V, Uusitupa M, Forsen TJ, Laakso M, Osmond C, Barker DJ: The effects of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ2 gene on insulin sensitivity and insulin metabolism interact with size at birth. Diabetes 2002;51:2321–2324.
38.
Harding J: The nutritional basis of the fetal origins of adult disease. Int J Epidemiol 2001;30:15–23.
39.
Barker DJP, Eriksson JG, Forsen T, Osmond C: Fetal origins of adult disease: strength of effects and biological basis. Int J Epidemiol 2002;31:1235–1239.
© 2005 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.